Immuron Travelan continued strong sales growth Sales Highlights: Global September 2024 Quarter AUD$1.5 million up 13% on prior quarter Australia September 2024 Quarter AUD$1.0 million up 3% on prior quarter North America

Travelan continued strong sales growth

Melbourne, Australia, October 15, 2024: Immuron

Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to announce continued

strong sales growth (unaudited) of Travelan , an over-the-counter immune supplement that targets pathogenic bacteria and

the toxins they produce in the gastrointestinal (GI) tract.

Flavio Palumbo, Chief Commercial Officer said

"As anticipated, we are achieving strong growth in North America with continued growth in Australia. We have secured core ranging

in another nine pharmacy banner groups in Australia. We had our strongest monthly sales on amazon.com in the US. We now have distribution

in ten pharmacy/grocery retailers in Canada."

Sales of Travelan increased 3%

to AUD $1.007 million during September 2024 Quarter compared to AUD $0.983 million for June 2024 Quarter.

Sales of Travelan increased 48%

to AUD $0.456 million in the September 2024 Quarter compared to AUD $0.309 million in the June 2024 Quarter.

This release has been authorised by the directors of Immuron Limited.

Chief Executive Officer

Ph: +61 (0)3 9824 5254

is an orally administered passive immunotherapy that prophylactically reduces the likelihood of contracting travelers' diarrhea,

a digestive tract disorder that is commonly caused by pathogenic bacteria and the toxins they produce.

Travelan is a purified tablet preparation of hyper-immune bovine antibodies and other factors, which when taken with

meals bind to diarrhea-causing bacteria and prevent colonization and the pathology associated with traveler's diarrhea. In Australia,

Travelan is a listed medicine on the Australian Register for Therapeutic Goods (AUST L 106709) and is indicated to reduce

the risk of Traveler's Diarrhea, reduce the risk of minor gastro-intestinal disorders and is antimicrobial. In Canada, Travelan

is a licensed natural health product (NPN 80046016) and is indicated to reduce the risk of Traveler's Diarrhea. In the U.S.,

Travelan is sold as a dietary supplement for digestive tract protection.

About Traveler's diarrhea

is a gastrointestinal infection with symptoms that include loose, watery (and occasionally bloody) stools, abdominal cramping, bloating,

and fever, Enteropathogenic bacteria are responsible for most cases, with enterotoxigenic Escherichia coli (ETEC) playing a dominant

Immuron Limited (ASX:

IMC, NASDAQ: IMRN), is an Australian biopharmaceutical company focused on developing and commercializing orally delivered targeted polyclonal

antibodies for the treatment of inflammatory mediated and infectious diseases.

For more information

visit: https://www.immuron.com.au

FORWARD-LOOKING STATEMENTS:

This press release may contain "forward-looking

statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934,

each as amended. Such statements include, but are not limited to, any statements relating to our growth strategy and product development

programs and any other statements that are not historical facts. Forward-looking statements are based on management's current expectations

and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock

value. Factors that could cause actual results to differ materially from those currently anticipated include: risks relating to our growth

strategy; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; risks relating to the

results of research and development activities; risks relating to the timing of starting and completing clinical trials; uncertainties

relating to preclinical and clinical testing; our dependence on third-party suppliers; our ability to attract, integrate and retain key

personnel; the early stage of products under development; our need for substantial additional funds; government regulation; patent and

intellectual property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation

or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in

our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.